Unintended Consequences of the Inflation Reduction Act: Clinical Development Toward Subsequent Indications
The Inflation Reduction Act will likely change incentives surrounding single-indication launches and postapproval research for additional indications in small molecule drugs, affecting patient access.
Read More
Good Health Policy Requires High-Quality Evidence. Let’s Remember That With Drug Pricing.
In the health spending debate, what policy makers need most is an honest, realistic, and evidence-based discussion. Unfortunately, many studies in the public arena fall far short.